Moderna (MRNA) Debt Ratio (2025 - 2026)
Moderna (MRNA) posted quarterly Debt Ratio of 0.05 for Q2 2026, up 4.99% on a QoQ basis from 0.05 in Q1 2026.
Moderna (MRNA) Debt Ratio (2025 - 2026) Analysis & Trends
Moderna has reported Debt Ratio for 2 years, with the latest figure at 0.05 in Q2 2026.
- Debt Ratio for Q2 2026 came in at 0.05, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was 0.05 (changed N/A YoY), and the FY2025 annual result was 0.05, changed N/A from the prior year.
- Debt Ratio grew to 0.05 in Q2 2026, from 0.05 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.05 in Q2 2026 and troughed at 0.05 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 0.47 |
| 10 | Roivant Sciences | 26.36 Bn | 26.36 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.05 |
| Mar 31, 2026 | 0.05 |
| Dec 31, 2025 | 0.05 |